title: Differential roles of fibrinogen and von Willebrand factor on clot formation and platelet adhesion in reconstituted and immune thrombocytopenia.
abstract: BACKGROUND
  Bleeding tendencies in immune thrombocytopenia (ITP) do not always correlate with the number of platelets, suggesting platelet function variation. We used a model of normal whole blood thrombocytopenia to compare platelet function and other hemostatic variables with ITP patients. We further investigated the effect of in vitro spiking with von Willebrand factor (vWF) and fibrinogen on platelet function and hemostatic variables.
  
  
  METHODS
  The Cone and Plate(let) Analyzer was used to measure platelet adhesion (surface coverage [SC], %) and aggregation (average size, μm(2)) under defined shear rate (1200 s(-1)). Rotational thromboelastometry was used to determine variables of clot formation triggered by CaCl(2) and tissue factor.
  
  
  RESULTS
  In both the model of thrombocytopenia as well as in ITP, the SC and to some extent the average size were correlated to the platelet number over a range of 5 to 80 × 10(6)/mL. The results obtained for most ITP samples were within the boundaries of the lower and upper limits set by the whole blood model of thrombocytopenia. The addition of 2 U/mL vWF (Haemate-P) to whole blood (calculated to plasma volume) results in an increase in the SC and average size without affecting clot formation. Spiking with fibrinogen (100 and 300 mg/dL) did not affect platelet deposition but improved clot formation.
  
  
  CONCLUSIONS
  Using a model of whole blood thrombocytopenia enables us to establish reference variables for the Cone and Plate(let) Analyzer and rotational thromboelastometry and to assess platelet function and clot formation in the presence of severe thrombocytopenia. We demonstrated that in most cases of ITP, platelet function is comparable to normal platelets. This work also suggests that vWF and fibrinogen differentially affect primary and secondary hemostasis and therefore both may perform a function in the bleeding phenotype and possibly may be considered for treatment in patients with ITP.
authors.affiliation: Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors.forename: Mudi
authors.initials: M
authors.lastname: Misgav
authors.forename: Boris
authors.initials: B
authors.lastname: Shenkman
authors.forename: Ivan
authors.initials: I
authors.lastname: Budnik
authors.forename: Yulia
authors.initials: Y
authors.lastname: Einav
authors.forename: Uri
authors.initials: U
authors.lastname: Martinowitz
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005340:Fibrinogen / Q000378:metabolism*; D006470:Hemorrhage / Q000097:blood / Q000209:etiology* / Q000276:immunology; D006487:Hemostasis; D006801:Humans; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D010973:Platelet Adhesiveness; D010974:Platelet Aggregation; D010976:Platelet Count; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000097:blood / Q000150:complications* / Q000276:immunology; D013916:Thrombelastography; D013921:Thrombocytopenia / Q000097:blood / Q000150:complications*; D013927:Thrombosis / Q000097:blood / Q000209:etiology* / Q000276:immunology; D055815:Young Adult; D014841:von Willebrand Factor / Q000378:metabolism*
chemical_list: D014841:von Willebrand Factor; D005340:Fibrinogen